Page last updated: 2024-08-23

silybin and Protein Aggregation, Pathological

silybin has been researched along with Protein Aggregation, Pathological in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bongiorno, C; D'Urso, L; Di Fabio, G; Diomede, L; Galati, C; Grasso, G; La Rosa, C; Lolicato, F; Milardi, D; Monaco, I; Romanucci, V; Romeo, M; Salmona, M; Sciacca, MFM; Spinella, N; Zarrelli, A1
Chen, X; Duan, S; Fang, S; Gu, H; Guan, X; Huang, J; Li, Q; Lin, R; Liu, X; Sun, X; Xu, J; Yan, Y; Yao, Z; Zhang, T1
Biedermann, D; Chondrogianni, N; Filippopoulou, K; Křen, V; Lefaki, M; Papaevgeniou, N; Paraskevopoulou, A1

Other Studies

3 other study(ies) available for silybin and Protein Aggregation, Pathological

ArticleYear
Inhibition of Aβ Amyloid Growth and Toxicity by Silybins: The Crucial Role of Stereochemistry.
    ACS chemical neuroscience, 2017, 08-16, Volume: 8, Issue:8

    Topics: Amyloid beta-Peptides; Animals; Animals, Genetically Modified; Blotting, Western; Caenorhabditis elegans; Dose-Response Relationship, Drug; Microscopy, Atomic Force; Microscopy, Electron, Transmission; Molecular Dynamics Simulation; Molecular Structure; Neuroprotective Agents; Peptide Fragments; Protein Aggregation, Pathological; Protein Conformation; Silybin; Silymarin

2017
Silibinin inhibits acetylcholinesterase activity and amyloid β peptide aggregation: a dual-target drug for the treatment of Alzheimer's disease.
    Neurobiology of aging, 2015, Volume: 36, Issue:5

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; Dentate Gyrus; Female; Male; Mice, Transgenic; Nerve Regeneration; Phytotherapy; Protein Aggregation, Pathological; Rats, Sprague-Dawley; Silybin; Silybum marianum; Silymarin

2015
2,3-Dehydrosilybin A/B as a pro-longevity and anti-aggregation compound.
    Free radical biology & medicine, 2017, Volume: 103

    Topics: Animals; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Cell Line; Cell Survival; CHO Cells; Cricetinae; Cricetulus; Drug Evaluation, Preclinical; Glucose Transport Proteins, Facilitative; Humans; Longevity; Oxidative Stress; Protective Agents; Protein Aggregation, Pathological; Silybin; Silymarin

2017